Zydus receives final approval for Lansoprazole DR Capsules

Zydus Cadila has received the final approval form the US FDA to market Lansoprazole DR capsules in the strengths of 15mg and 30 mg. The drug falls in the anti-ulcerant segment.The drug falls under the anti-ulcerant segment.

The estimated sales in 2012 as per IMS for Lansoprazole Dr capsules was $501 million

The group now has 81 approvals and has so far filed 186 ANDAs since the commencement of filing process in FY04.